Skip to main content

Paolini John F.'s Form 4 filing

Kiniksa Pharmaceuticals International, plc (KNSA) · filed May 5, 2026

Accession no.
0001741533-26-000008
Filed
May 5, 2026
Trade date
May 1, 2026
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.14M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Paolini John F.CIK 0001741533Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 1, 2026Class A Ordinary ShareMOption exerciseAcquired+58,424$10.36+$605,272.64124,047Direct
May 1, 2026Class A Ordinary ShareSSaleDisposed−37,327$53.52−$1,997,741.0486,720Direct
May 1, 2026Class A Ordinary ShareSSaleDisposed−21,097$54.04−$1,140,081.8865,623Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 1, 2026Class A Ordinary ShareMOption exerciseDisposed−58,424$0.00$029,670Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)